Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability

被引:57
作者
Olpin, Simon E. [1 ]
机构
[1] Sheffield Childrens Hosp, Dept Clin Chem, Sheffield S10 2TH, S Yorkshire, England
关键词
CHAIN 3-HYDROXYACYL-COA DEHYDROGENASE; ACYL-COA DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE-I; TRIFUNCTIONAL PROTEIN-DEFICIENCY; MITOCHONDRIAL ENERGY HOMEOSTASIS; RENAL TUBULAR-ACIDOSIS; RAT-LIVER MITOCHONDRIA; BETA-OXIDATION; FOLLOW-UP; BIOENERGETIC DYSFUNCTION;
D O I
10.1007/s10545-013-9611-5
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Fatty acids are a major fuel for the body and fatty acid oxidation is particularly important during fasting, sustained aerobic exercise and stress. The myocardium and resting skeletal muscle utilise long-chain fatty acids as a major source of energy. Inherited disorders affecting fatty acid oxidation seriously compromise the function of muscle and other highly energy-dependent tissues such as brain, nerve, heart, kidney and liver. Such defects encompass a wide spectrum of clinical disease, presenting in the neonatal period or infancy with recurrent hypoketotic hypoglycaemic encephalopathy, liver dysfunction, hyperammonaemia and often cardiac dysfunction. In older children, adolescence or adults there is often exercise intolerance with episodic myalgia or rhabdomyolysis in association with prolonged aerobic exercise or other exacerbating factors. Some disorders are particularly associated with toxic metabolites that may contribute to encephalopathy, polyneuropathy, axonopathy and pigmentary retinopathy. The phenotypic diversity encountered in defects of fat oxidation is partly explained by genotype/phenotype correlation and certain identifiable environmental factors but there remain many unresolved questions regarding the complex interaction of genetic, epigenetic and environmental influences that dictate phenotypic expression. It is becoming increasingly clear that the view that most inherited disorders are purely monogenic diseases is a naive concept. In the future our approach to understanding the phenotypic diversity and management of patients will be more realistically achieved from a polygenic perspective.
引用
收藏
页码:645 / 658
页数:14
相关论文
共 118 条
[1]
Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development [J].
Abbott, Barbara D. .
REPRODUCTIVE TOXICOLOGY, 2009, 27 (3-4) :246-257
[2]
Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency [J].
Andresen, BS ;
Olpin, S ;
Poorthuis, BJHM ;
Scholte, HR ;
Vianey-Saban, C ;
Wanders, R ;
Ijlst, L ;
Morris, A ;
Pourfarzam, M ;
Bartlett, K ;
Baumgartner, ER ;
deKlerk, JBC ;
Schroeder, LD ;
Corydon, TJ ;
Lund, H ;
Winter, V ;
Bross, P ;
Bolund, L ;
Gregersen, N .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (02) :479-494
[3]
[Anonymous], 2000, NATL DIET NUTR SURVE
[4]
Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts [J].
Bastin, Jean ;
Lopes-Costa, Alexandra ;
Djouadi, Fatima .
HUMAN MOLECULAR GENETICS, 2011, 20 (10) :2048-2057
[5]
Inborn errors of mitochondrial fatty acid oxidation [J].
Bennett, MJ ;
Rinaldo, P ;
Strauss, AW .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2000, 37 (01) :1-44
[6]
RATE-DEPENDENT DISTAL RENAL TUBULAR-ACIDOSIS AND CARNITINE PALMITOYLTRANSFERASE-I DEFICIENCY [J].
BERGMAN, AJIW ;
DONCKERWOLCKE, RAMG ;
DURAN, M ;
SMEITINK, JAM ;
MOUSSON, B ;
VIANEYSABAN, C ;
POLLTHE, BT .
PEDIATRIC RESEARCH, 1994, 36 (05) :582-588
[7]
Phosphatidylcholine molecular species in lung surfactant - Composition in relation to respiratory rate and lung development [J].
Bernhard, W ;
Hoffmann, S ;
Dombrowsky, H ;
Rau, GA ;
Kamlage, A ;
Kappler, M ;
Haitsma, JJ ;
Freihorst, J ;
von der Hardt, H ;
Poets, CF .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 25 (06) :725-731
[8]
Metabolic and hormonal responses to exercise in children and adolescents [J].
Boisseau, N ;
Delamarche, P .
SPORTS MEDICINE, 2000, 30 (06) :405-422
[9]
Long-Term Follow-Up of Bezafibrate Treatment in Patients With the Myopathic Form of Carnitine Palmitoyltransferase 2 Deficiency [J].
Bonnefont, J. P. ;
Bastin, J. ;
Laforet, P. ;
Aubey, F. ;
Mogenet, A. ;
Romano, S. ;
Ricquier, D. ;
Gobin-Limballe, S. ;
Vassault, A. ;
Behin, A. ;
Eymard, B. ;
Bresson, J. L. ;
Djouadi, F. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (01) :101-108
[10]
Bonnefont JP, 1996, AM J HUM GENET, V58, P971